InsiMine的动态

Dr.Evidence upgrades its AI-driven platform with new features to streamline regulatory processes and accelerate time-to-market for life sciences products. Read the full news - https://lnkd.in/djP3s6Zg #LifeSciences #RegulatoryIntelligence #DrugDevelopment #AIDrivenSolutions #PharmaInnovation #DrEvidence #GenerativeAI #HealthcareInnovation #Biotech #MarketAccess #techedgeai

?? ?? Reposting in case you missed it ?? ?? How far can we push the limits of automation in clinical trials? Join leaders from AbbVie, ThoughtSphere, and ZS as they discuss: ? Conditions for a fully autonomous ClinOps model ? Balancing risk with innovation ? The role of technology and regulatory frameworks in shaping the future ?? January 23, 2025 ? 11 AM ET Don't miss this pivotal discussion. Secure your spot today! ?? https://lnkd.in/gXBwRTE2 #ClinicalTrials #GenAI #FutureIsNow #Biopharma #Webinar

Pharma companies are approaching market access planning early, using real-world data and AI. https://ow.ly/WlRc50SEHW1 In Life Science Leader, MMIT and The Dedham Group experts explain why increased financial pressures have resulted in greater investment in market access. #MarketAccess #Pharma #PharmaCompanies

CERTARA CLIENTS: We invite you to our first client summit, CERTAINTY by Certara, from May 14-16 in Philadelphia. https://ow.ly/5ELu50QRyCy Learn about the business impact of biosimulation and model-informed drug development (MIDD), digital data flows, and AI's influence on regulatory sciences. Case studies from industry leaders like AstraZeneca, Arcus, Genentech, GSK, and more will be presented. ?? Day 1 features Phoenix and Pinnacle 21 user groups, a mechanistic modeling workshop, and a roundtable on Generative AI in Medical Writing. ?? Day 2 kicks off with a keynote by Dr. Scott Gottlieb, former US FDA Commissioner, in a fireside chat with William Feehery Certara's CEO. Gain insights into lessons learned to advance medicine. ?? Day 3 features more customer success stories and dedicated topic tracks on the Value of MIDD, Clinical Data, and Regulatory Sciences Strategy, Automation & Insights Don't miss this opportunity to network, collaborate, and shape the future of drug development. To learn more, visit https://ow.ly/5ELu50QRyCy #CERTAINTY #ClientSummit #DrugDevelopment #Biosimulation

Facing challenges in early phase drug discovery? Traditional methods are costly and resource-heavy. Discover how AI is set to address these issues and transform the future of drug design & development! Stay tuned for more insights. #AIinPharma #drugdiscovery #drugdevelopment #FutureOfMedicine #pharmatech #AIRevolution #costeffective #TransformingHealthcare #healthtech #CyberAIDD?

Data plays a critical role in modern healthcare, driving innovation and efficiency in every aspect—from drug discovery to patient care. Traditional drug discovery methods relied on trial and error in "wet labs," leading to high costs, inefficiencies, and long timelines. Today, data-driven approaches transform this process, enabling targeted research, predictive modeling, and streamlined clinical trials. By leveraging data, we can fast-track breakthroughs and reduce the cost of therapies, ensuring better patient access. Click the link to read more about how data is reshaping drug discovery on our blog on our blog post titled In-vitro to In-Silico: Is Data-Driven Drug Discovery the Future. (https://lnkd.in/dHUu9cjX) #DataInHealthcare #PharmaInnovation #ClinicalResearch #DrugDiscovery #ClinicalDataManagement #ClinicalResearchOrganisation #CRO

Lots of GenAI talk nowadays but so few seem relevant to the regulated industry of LS. Here is one that is sure to hit the mark! Excited about the potential of #GenAI in life sciences? ?? Don't miss our upcoming webinar on May 7th! Join us as industry thought leaders dive into how GenAI can address challenges and accelerate breakthroughs in drug development. Register now: https://2.sas.com/6042bUacC

Pharma companies are approaching market access planning early, using real-world data and AI. https://ow.ly/wSwR50SEI0T In Life Science Leader, MMIT and The Dedham Group experts explain why increased financial pressures have resulted in greater investment in market access. #MarketAccess #Pharma #PharmaCompanies

?? ?????????????? ??????????????: We invite you to our inaugural client summit, CERTAINTY, from May 14-16 in Philadelphia at Convene. https://lnkd.in/eNiTGkgn Learn about the business impact of biosimulation and model-informed drug development (MIDD), digital data flows, and AI's influence on regulatory sciences. Case studies from industry leaders like AstraZeneca, Arcus, Genentech, GSK, and more will be presented. ?? Day 1 features Phoenix and Pinnacle 21 user groups, a mechanistic modeling workshop, and a roundtable on Generative AI in Medical Writing. ?? Day 2 kicks off with a keynote by Dr. @Scott Gottlieb, former US FDA Commissioner, in a fireside chat with @Bill Feehery, Certara's CEO. Gain insights into lessons learned to advance medicine. ?? Day 3 features more customer success stories and dedicated topic tracks on the Value of MIDD, Clinical Data, and Regulatory Sciences Strategy, Automation & Insights Don't miss this opportunity to network, collaborate, and shape the future of drug development. To learn more, visit https://lnkd.in/eNiTGkgn #CERTAINTY #ClientSummit #DrugDevelopment #Biosimulation